

2019 Future of Actinic (Solar) Keratosis R&D Pipeline Drugs and Companies- Analysis of Global Actinic (Solar) Keratosis Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/2858B01D501EN.html>

Date: January 2019

Pages: 50

Price: US\$ 2,199.00 (Single User License)

ID: 2858B01D501EN

Abstracts

The global demand for Actinic (Solar) Keratosis treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Actinic (Solar) Keratosis pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Actinic (Solar) Keratosis pipeline companies from advancing their products into Phase 3 or Phase 4.

Actinic (Solar) Keratosis Report Description

The H1 2019 pipeline review report on Actinic (Solar) Keratosis pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Actinic (Solar) Keratosis pipeline compounds.

The Actinic (Solar) Keratosis pipeline guide presents information on all active drugs currently being developed for Actinic (Solar) Keratosis. The research work provides details of active therapeutic candidates in different phases including discovery,

research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Actinic (Solar) Keratosis pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Actinic (Solar) Keratosis drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Actinic (Solar) Keratosis product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Actinic (Solar) Keratosis pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Actinic (Solar) Keratosis pipeline report includes

An overview of Actinic (Solar) Keratosis disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of pipeline compounds

Company wise list of pipeline compounds

Mechanism of Action wise pipeline compounds

For each pipeline product, the following details are provided-

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Actinic (Solar) Keratosis pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Actinic (Solar) Keratosis pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into the market through in-depth strategic analysis review

Know the list of companies participating in global Actinic (Solar) Keratosis pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and

company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL ACTINIC (SOLAR) KERATOSIS PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Report Guide and Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Actinic (Solar) Keratosis Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
- 3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
- 3.4 Companies involved in Actinic (Solar) Keratosis pipeline, H1- 2019
- 3.5 Mechanism of Action wise Actinic (Solar) Keratosis Pipeline Candidates

4. AMDERMA PHARMACEUTICALS LLC ACTINIC (SOLAR) KERATOSIS PIPELINE DETAILS

- 4.1 AmDerma Pharmaceuticals LLC Business Profile
- 4.2 AmDerma Pharmaceuticals LLC Actinic (Solar) Keratosis Drug Details
 - 4.2.1 Drug Snapshot
 - 4.2.1.1 Originator
 - 4.2.1.2 Collaborator/Co-Developer
 - 4.2.1.3 Route of Administration
 - 4.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 4.2.1.5 Area
 - 4.2.1.6 Type of Molecular Entity
- 4.3 Current Status
- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5. ATHENEX INC ACTINIC (SOLAR) KERATOSIS PIPELINE DETAILS

- 5.1 Athenex Inc Business Profile
- 5.2 Athenex Inc Actinic (Solar) Keratosis Drug Details
 - 5.2.1 Drug Snapshot
 - 5.2.1.1 Originator
 - 5.2.1.2 Collaborator/Co-Developer
 - 5.2.1.3 Route of Administration
 - 5.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 5.2.1.5 Area
 - 5.2.1.6 Type of Molecular Entity
- 5.3 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6. G&E CORPORATION ACTINIC (SOLAR) KERATOSIS PIPELINE DETAILS

- 6.1 G&E Corporation Business Profile
- 6.2 G&E Corporation Actinic (Solar) Keratosis Drug Details
 - 6.2.1 Drug Snapshot
 - 6.2.1.1 Originator
 - 6.2.1.2 Collaborator/Co-Developer
 - 6.2.1.3 Route of Administration
 - 6.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 6.2.1.5 Area
 - 6.2.1.6 Type of Molecular Entity
- 6.3 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7. GAGE DEVELOPMENT COMPANY LLC ACTINIC (SOLAR) KERATOSIS PIPELINE DETAILS

- 7.1 Gage Development Company LLC Business Profile

7.2 Gage Development Company LLC Actinic (Solar) Keratosis Drug Details

7.2.1 Drug Snapshot

7.2.1.1 Originator

7.2.1.2 Collaborator/Co-Developer

7.2.1.3 Route of Administration

7.2.1.4 Orphan Drug/Fast Track/Special Designation

7.2.1.5 Area

7.2.1.6 Type of Molecular Entity

7.3 Current Status

7.4 Drug Overview

7.5 Drug Mechanism of Action

7.6 Clinical/Pre-clinical Trial Details

7.7 Latest Drug Developments

8. NANOLOGY LLC ACTINIC (SOLAR) KERATOSIS PIPELINE DETAILS

8.1 Nanology LLC Business Profile

8.2 Nanology LLC Actinic (Solar) Keratosis Drug Details

8.2.1 Drug Snapshot

8.2.1.1 Originator

8.2.1.2 Collaborator/Co-Developer

8.2.1.3 Route of Administration

8.2.1.4 Orphan Drug/Fast Track/Special Designation

8.2.1.5 Area

8.2.1.6 Type of Molecular Entity

8.3 Current Status

8.4 Drug Overview

8.5 Drug Mechanism of Action

8.6 Clinical/Pre-clinical Trial Details

8.7 Latest Drug Developments

9. NEONC TECHNOLOGIES INC ACTINIC (SOLAR) KERATOSIS PIPELINE DETAILS

9.1 Neonc Technologies Inc Business Profile

9.2 Neonc Technologies Inc Actinic (Solar) Keratosis Drug Details

9.2.1 Drug Snapshot

9.2.1.1 Originator

9.2.1.2 Collaborator/Co-Developer

- 9.2.1.3 Route of Administration
- 9.2.1.4 Orphan Drug/Fast Track/Special Designation
- 9.2.1.5 Area
- 9.2.1.6 Type of Molecular Entity
- 9.3 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

10. NOVARTIS AG ACTINIC (SOLAR) KERATOSIS PIPELINE DETAILS

- 10.1 Novartis AG Business Profile
- 10.2 Novartis AG Actinic (Solar) Keratosis Drug Details
 - 10.2.1 Drug Snapshot
 - 10.2.1.1 Originator
 - 10.2.1.2 Collaborator/Co-Developer
 - 10.2.1.3 Route of Administration
 - 10.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 10.2.1.5 Area
 - 10.2.1.6 Type of Molecular Entity
- 10.3 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details
- 10.7 Latest Drug Developments

11. OJER PHARMA ACTINIC (SOLAR) KERATOSIS PIPELINE DETAILS

- 11.1 OJER Pharma Business Profile
- 11.2 OJER Pharma Actinic (Solar) Keratosis Drug Details
 - 11.2.1 Drug Snapshot
 - 11.2.1.1 Originator
 - 11.2.1.2 Collaborator/Co-Developer
 - 11.2.1.3 Route of Administration
 - 11.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 11.2.1.5 Area
 - 11.2.1.6 Type of Molecular Entity
- 11.3 Current Status

- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details
- 11.7 Latest Drug Developments

12. PFIZER INC ACTINIC (SOLAR) KERATOSIS PIPELINE DETAILS

- 12.1 Pfizer Inc Business Profile
- 12.2 Pfizer Inc Actinic (Solar) Keratosis Drug Details
 - 12.2.1 Drug Snapshot
 - 12.2.1.1 Originator
 - 12.2.1.2 Collaborator/Co-Developer
 - 12.2.1.3 Route of Administration
 - 12.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 12.2.1.5 Area
 - 12.2.1.6 Type of Molecular Entity
- 12.3 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

13. PROMIUS PHARMA LLC ACTINIC (SOLAR) KERATOSIS PIPELINE DETAILS

- 13.1 Promius Pharma LLC Business Profile
- 13.2 Promius Pharma LLC Actinic (Solar) Keratosis Drug Details
 - 13.2.1 Drug Snapshot
 - 13.2.1.1 Originator
 - 13.2.1.2 Collaborator/Co-Developer
 - 13.2.1.3 Route of Administration
 - 13.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 13.2.1.5 Area
 - 13.2.1.6 Type of Molecular Entity
- 13.3 Current Status
- 13.4 Drug Overview
- 13.5 Drug Mechanism of Action
- 13.6 Clinical/Pre-clinical Trial Details
- 13.7 Latest Drug Developments

14. SINGH BIOTECHNOLOGY LLC ACTINIC (SOLAR) KERATOSIS PIPELINE DETAILS

- 14.1 Singh Biotechnology LLC Business Profile
- 14.2 Singh Biotechnology LLC Actinic (Solar) Keratosis Drug Details
 - 14.2.1 Drug Snapshot
 - 14.2.1.1 Originator
 - 14.2.1.2 Collaborator/Co-Developer
 - 14.2.1.3 Route of Administration
 - 14.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 14.2.1.5 Area
 - 14.2.1.6 Type of Molecular Entity
- 14.3 Current Status
- 14.4 Drug Overview
- 14.5 Drug Mechanism of Action
- 14.6 Clinical/Pre-clinical Trial Details
- 14.7 Latest Drug Developments

15. SWITCH BIOTECH ACTINIC (SOLAR) KERATOSIS PIPELINE DETAILS

- 15.1 Switch Biotech Business Profile
- 15.2 Switch Biotech Actinic (Solar) Keratosis Drug Details
 - 15.2.1 Drug Snapshot
 - 15.2.1.1 Originator
 - 15.2.1.2 Collaborator/Co-Developer
 - 15.2.1.3 Route of Administration
 - 15.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 15.2.1.5 Area
 - 15.2.1.6 Type of Molecular Entity
- 15.3 Current Status
- 15.4 Drug Overview
- 15.5 Drug Mechanism of Action
- 15.6 Clinical/Pre-clinical Trial Details
- 15.7 Latest Drug Developments

16. VIDAC PHARMA LTD ACTINIC (SOLAR) KERATOSIS PIPELINE DETAILS

- 16.1 Vidac Pharma Ltd Business Profile
- 16.2 Vidac Pharma Ltd Actinic (Solar) Keratosis Drug Details

16.2.1 Drug Snapshot

16.2.1.1 Originator

16.2.1.2 Collaborator/Co-Developer

16.2.1.3 Route of Administration

16.2.1.4 Orphan Drug/Fast Track/Special Designation

16.2.1.5 Area

16.2.1.6 Type of Molecular Entity

16.3 Current Status

16.4 Drug Overview

16.5 Drug Mechanism of Action

16.6 Clinical/Pre-clinical Trial Details

16.7 Latest Drug Developments

17. LATEST ACTINIC (SOLAR) KERATOSIS DRUG PIPELINE DEVELOPMENTS, 2019

18. APPENDIX

18.1 About Us

18.2 Sources and Methodology

18.3 Contact Information

I would like to order

Product name: 2019 Future of Actinic (Solar) Keratosis R&D Pipeline Drugs and Companies- Analysis of Global Actinic (Solar) Keratosis Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/2858B01D501EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2858B01D501EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970